Survival statistics for ovarian cancer

Survival statistics for ovarian cancer are very general estimates and must be interpreted very carefully. Because these statistics are based on the experience of groups of women, they cannot be used to predict a particular woman’s chances of survival.

There are many different ways to measure and report cancer survival statistics. Your doctor can explain the statistics for ovarian cancer and what they mean to you.

Net survival

Net survival represents the probability of surviving cancer in the absence of other causes of death. It is used to give an estimate of the percentage of people who will survive their cancer.

In Canada, the 5-year net survival for ovarian cancer is 45%. This means that about 45% of women diagnosed with ovarian cancer will survive for at least 5 years.

Survival by stage and tumour type

Survival varies with each stage and particular tumour type of ovarian cancer. Generally, the earlier ovarian cancer is diagnosed and treated, the better the outcome.

Survival by stage and tumour type of ovarian cancer is reported as 5-year relative survival. Relative survival looks at how likely people with cancer are to survive after their diagnosis compared to people in the general population who do not have cancer, but who share similar characteristics (such as age and sex).

There are no specific Canadian statistics available for the different stages and types of ovarian cancer. The following information comes from a variety of sources. It may include statistics from other countries that are likely to have similar outcomes as in Canada.

Epithelial ovarian cancer survival

Stage

5-year relative survival

1

90%

1A

94%

1B

92%

1C

85%

2

70%

2A

78%

2B

73%

2C

57%

3

39%

3A

59%

3B

52%

3C

39%

4

17%

Ovarian stromal tumour survival

Stage

5-year relative survival

1

95%

2

78%

3

65%

4

35%

Ovarian germ cell tumour survival

Stage

5-year relative survival

1

98%

2

94%

3

87%

4

69%

Borderline ovarian tumour survival

Stage

5-year relative survival

10-year relative survival

1

99%

97%

2

98%

90%

3

96%

88%

4

77%

69%

Primary peritoneal carcinoma survival

The overall 5-year survival for primary peritoneal carcinoma is about 20%. Long-term survival may be better than 20% if the treatment plan includes chemotherapy.

Questions about survival

Talk to your doctor about your prognosis. A prognosis depends on many factors, including:

  • your health history
  • the type of cancer
  • the grade
  • the stage
  • certain characteristics of the cancer
  • the treatments chosen
  • how the cancer responds to treatment

Only a doctor familiar with these factors can put all of this information together with survival statistics to arrive at a prognosis.

Expert review and references

  • American Cancer Society. Ovarian Cancer. 2014. http://www.cancer.org/.
  • Canadian Cancer Statistics Advisory Committee. Canadian Cancer Statistics 2019. Toronto, ON: Canadian Cancer Society; 2019. https://cancer.ca/en/research/cancer-statistics/past-editions.
  • Eskander RN, Diaz-Montes TP, Vang R, Armstrong DK, Bristow RE. Borderline tumors and other rare epithelial tumors of the ovary. Raghavan D, Blanke CD, Honson DH, et al (eds.). Textbook of Uncommon Cancer. 4th ed. Wiley Blackwell; 2012: 35: 497-506.
  • Selman AE, Copeland LJ. Extraovarian primary peritoneal carcinomas. Raghavan D, Blanke CD, Honson DH, et al (eds.). Textbook of Uncommon Cancer. 4th ed. Wiley Blackwell; 2012: 34: 485-495.

Medical disclaimer

The information that the Canadian Cancer Society provides does not replace your relationship with your doctor. The information is for your general use, so be sure to talk to a qualified healthcare professional before making medical decisions or if you have questions about your health.

We do our best to make sure that the information we provide is accurate and reliable but cannot guarantee that it is error-free or complete.

The Canadian Cancer Society is not responsible for the quality of the information or services provided by other organizations and mentioned on cancer.ca, nor do we endorse any service, product, treatment or therapy.


1-888-939-3333 | cancer.ca | © 2024 Canadian Cancer Society